Caldwell Sutter Capital Inc. bought a new stake in shares of Solventum Co. (NYSE:SOLV – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 767 shares of the company’s stock, valued at approximately $41,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Fifth Lane Capital LP bought a new stake in shares of Solventum in the 1st quarter worth approximately $826,000. Boit C F David bought a new stake in Solventum in the first quarter worth $152,000. Mitsubishi UFJ Trust & Banking Corp bought a new stake in Solventum in the first quarter worth $5,747,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Solventum in the first quarter worth $209,000. Finally, LRI Investments LLC bought a new position in shares of Solventum during the first quarter valued at $43,000.
Solventum Stock Up 0.4 %
Solventum stock traded up $0.21 during mid-day trading on Wednesday, reaching $59.66. 914,209 shares of the stock traded hands, compared to its average volume of 2,091,954. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The firm’s 50-day simple moving average is $54.54. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31.
Wall Street Analysts Forecast Growth
SOLV has been the topic of a number of analyst reports. Bank of America dropped their price target on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 25th. Morgan Stanley cut their price target on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. The Goldman Sachs Group boosted their price objective on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Argus started coverage on Solventum in a research report on Monday, June 24th. They issued a “hold” rating for the company. Finally, Wells Fargo & Company dropped their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus price target of $58.25.
Read Our Latest Stock Analysis on Solventum
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
- Five stocks we like better than Solventum
- Energy and Oil Stocks Explained
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- What Are Dividend Contenders? Investing in Dividend Contenders
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- What is a Stock Market Index and How Do You Use Them?
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.